REFRACTORY OSTEOSARCOMA
Clinical trials for REFRACTORY OSTEOSARCOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY OSTEOSARCOMA trials appear
Sign up with your email to follow new studies for REFRACTORY OSTEOSARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Engineered immune cells take on Hard-to-Treat bone cancer
Disease control Recruiting nowThis early-stage trial tests a new treatment called FH-FOLR1 ST CAR T cells for people with advanced osteosarcoma that has come back or not responded to standard therapy. The treatment involves taking a patient's own immune cells, modifying them in a lab to recognize and attack c…
Matched conditions: REFRACTORY OSTEOSARCOMA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 26, 2026 04:01 UTC
-
New hope for young cancer patients: experimental drug targets tough tumors
Disease control Recruiting nowThis study tests a drug called tegavivint in children, teens, and young adults (ages 1 to 30) whose solid tumors have returned or not responded to standard therapy. The drug works by blocking a key signal that tells cancer cells to grow. The trial aims to find the safest dose, un…
Matched conditions: REFRACTORY OSTEOSARCOMA
Phase: PHASE1, PHASE2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated May 26, 2026 04:00 UTC
-
Immune cell army targets childhood cancers in new trial
Disease control Recruiting nowThis early-phase study tests a new treatment for children whose neuroblastoma or osteosarcoma has not responded to standard therapy or has returned. The approach combines specially grown immune cells (gamma delta T cells) from a healthy donor with several chemotherapy drugs and a…
Matched conditions: REFRACTORY OSTEOSARCOMA
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated May 26, 2026 03:59 UTC
-
New hope for hard-to-treat bone cancer? experimental drug combo enters human testing
Disease control Recruiting nowThis early-phase study tests a new drug called tegavivint combined with the chemotherapy gemcitabine in people whose osteosarcoma (a type of bone cancer) has returned or not responded to standard treatments. The main goal is to find the safest dose of tegavivint when given with g…
Matched conditions: REFRACTORY OSTEOSARCOMA
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated May 26, 2026 03:50 UTC
-
New hope for kids with tough cancers: two drug combos enter trial
Disease control Recruiting nowThis study is for children and young adults (ages 1 to 30) whose solid tumors have come back or never fully went away. It tests two different drug combinations that damage cancer cell DNA to kill the tumor. The goal is to find the safest dose and see if the tumors shrink or disap…
Matched conditions: REFRACTORY OSTEOSARCOMA
Phase: PHASE1, PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated May 26, 2026 03:49 UTC
-
New drug cocktail aims to halt bone cancer in young patients
Disease control Recruiting nowThis study tests two drugs, atezolizumab and cabozantinib, in teens and young adults (ages 12 and up) with osteosarcoma that has come back or spread. The goal is to see if this combination can slow or stop cancer growth. About 40 participants will receive the treatment to measure…
Matched conditions: REFRACTORY OSTEOSARCOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 20, 2026 11:53 UTC